SCHEMBL26136371

SCHEMBL26136371

Clc1cccc(Cc2noc(-c3ccc(CBr)cc3)n2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.61
NPC1 O15118 2/20 0.61
RAB9A P51151 1/20 0.61
ERCC1 P07992 1/20 0.52
ERCC4 Q92889 1/20 0.52
HPGD P15428 2/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
L3MBTL1 Q9Y468 4/20 0.49
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NOTUM Q6P988 1/20 0.46
TSHR P16473 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPK1 P28482 4/20 0.44
MAPT P10636 2/20 0.44
NR1I3 Q14994 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26090239 0.88 HTT (0.63) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL26090158 0.87 HTT (0.61) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL31024148 0.86 HTT (0.63) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL26090728 0.86 HTT (0.63) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL26425647 0.86 NPC1 (0.63) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL26090397 0.86 NPC1 (0.63) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL26089991 0.80 NPC1 (0.56) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL26425656 0.79 NPC1 (0.54) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL26090394 0.78 NPC1 (0.53) HTTNPC1RAB9AERCC1ERCC4
SCHEMBL30408552 0.78 NPC1 (0.53) HTTNPC1RAB9AERCC1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425513-A1 OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 CARMOT THERAPEUTICS, INC. 2024-12-26 US disclosed
EP-4419508-A2 OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 Carmot Therapeutics, Inc. (US) 2024-08-28 EP disclosed
CN-118302414-A Oxazole, oxadiazole and indole derivatives useful for inhibiting USP28 卡莫特医疗有限公司 2024-07-05 CN disclosed
WO-2023069721-A2 OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 CARMOT THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
WO-2023069721-A2 OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 CARMOT THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425513-A1 OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 USP28, USP25, USP39 HTT 2732/4885NPC1 3849/4885RAB9A 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.